Find research datasets worth reusing

opencc-by-4.0Dec 2024View details →

Dataset: Chromatographic data for publication Exploration and optimisation of structure-activity relationships of newtriazole-based C-terminal Hsp90 inhibitors towards in vivoanticancer potency

Bio-chromoatographic data caming from publication Exploration and optimisation of structure-activity relationships of new triazole-based C-terminal Hsp90 inhibitors towards in vivo anticancer potency

Fig. 5 in Constituents promoting osteogenesis from the fruits of Psoralea corylifolia and their structure-activity relationship study

Fig. 5. Effects of psoralidin (0.1 μM) and neobavaisoflavone (0.1 μM) on osteogenic differentiation and mineralisation in MC3T3-E1 cell without or with ICI (0.1 μM) treatment. (A1) Calcium nodules after induction for 16 days stained by 1% Alizarin Red S. (A2) Quantification assay of the calcium nodules. (B) ALP activity after induction for 7 days; *P <0.05, **P <0.01, ***P <0.001, vs Control group; ###P <0.001, vs corresponding group without ICI. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Fig. 18 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 18. The "source-category-activities" network of lignans. (The green nodes represent the source (families), the red nodes indicate the category, and the purple nodes emblem the activities). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Fig. 17 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 17. The potential structure-activity relationships of lignans in antitumor, anti-inflammatory and antioxidant effects.

Fig. 16 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 16. Structure based activity distribution. (A) The proportion of pharmacological activities; (B) distribution of bioactivities in different classification.

Fig. 15 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 15. Distribution of molecular resources analysis. (A) Main classifications of lignans; (B) distribution of lignan subclass structures; (C) distribution of lignans in top eight families.

opencc-zeroJul 2022View details →

Supplementary material 1 from: Yaseen Y, Kubba A, Shihab W, Tahtamouni L (2022) Synthesis, docking study, and structure-activity relationship of novel niflumic acid derivatives acting as anticancer agents by inhibiting VEGFR or EGFR tyrosine kinase activities. Pharmacia 69(3): 595-614. https://doi.org/10.3897/pharmacia.69.e86504

Figures S1, S2, Tables S1, S2

Fig. 1 in Constituents promoting osteogenesis from the fruits of Psoralea corylifolia and their structure-activity relationship study

Fig. 1. Structures of 37 undescribed compounds.

Fig. 6 in Constituents promoting osteogenesis from the fruits of Psoralea corylifolia and their structure-activity relationship study

Fig. 6. SPR sensorgrams of eight compounds and E2 binding to ERβ at various concentration.

Fig. 2 in Constituents promoting osteogenesis from the fruits of Psoralea corylifolia and their structure-activity relationship study

Fig. 2. Selected HMBC (H → C) and 1H–1H COSY (H–H) correlations of undescribed compounds.

Fig. 3 in Constituents promoting osteogenesis from the fruits of Psoralea corylifolia and their structure-activity relationship study

Fig. 3. ORTEP drawing of compounds 1, 7, 8 and 33.

Fig. 14 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 14. The newly reported compounds of polymeric lignans.

Fig. 12 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 12. The newly reported compounds of seco-lignans.

Fig. 13 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 13. The newly reported compounds of norlignans.

Fig. 10 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 10. The newly reported compounds of benzofuran lignans.

Fig. 11 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 11. The newly reported compounds of oxyneolignans and non-oxyneolignans.

Fig. 5 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 5. The newly reported compounds of arylnaphthalenelactones lignans.

Fig. 6 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 6. The newly reported compounds of furofuran lignans.

Fig. 8 in Review of lignans from 2019 to 2021: Newly reported compounds, diverse activities, structure-activity relationships and clinical applications

Fig. 8. Basic skeletons of neolignans.